{"url_path":"/sec/bfnh/10-q/2026/item-2","section_key":"item-2","section_title":"Item 2 UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-19","source_url":"https://www.sec.gov/Archives/edgar/data/1310488/0001091818-26-000077-index.html","accession_number":"0001091818-26-000077","cik":"0001310488","ticker":"BFNH","issuer_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1310488/0001091818-26-000077-index.html","primary_entity_key":"0001310488","primary_entity_name":"BIOFORCE NANOSCIENCES HOLDINGS, INC."},"word_count":128,"has_tables":true,"body_markdown":"**ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**\n\n \n\n**2026**\n\n \n\nSubsequent to the close of the March 31, 2026 quarter, in April 2026,\nthe board of directors received a conversion notice from Nauri Dean Ahmad from whom the Company had borrowed $10,000. In accordance with\nthe loan document between Mr. Ahmad and the Company, Mr Ahmad was entitled to $11,000 in principal and interest repayment and 3,000 restricted\nshares as a premium for giving the Company a loan.  Mr. Ahmad received 24,250 shares of restricted 144 common stock on April 16,\n2026, based on the closing price on that day.\n\n \n\n**2025**\n\n \n\nOn January 24, 2025, Company's Board approved the issuance of 4,250,000\nrestricted 144 shares of common stock to pay for accrued officer and director fees."}